What happened with LAB today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Standard BioTools helps university researchers, biopharmaceutical companies and research laboratories study cells, tissues and genes. Its CyTOF instruments measure many protein markers in individual cells, while Hyperion maps protein markers within tissue. Biomark X9 uses tiny fluid channels to run many gene-analysis reactions together. The company retained these mass cytometry and microfluidics businesses after selling its SomaScan protein-analysis business to Illumina.
Customers pay for instruments, the consumables used to run experiments, and support services. Consumables are the largest revenue line, and together with instruments account for most revenue. Consumables sales depend on how many installed instruments remain in use and how often laboratories use them. Services include maintenance, installation and training.
Demand depends on customers’ research budgets and willingness to adopt its systems. One genomics customer contributes a meaningful share of revenue, though no customer dominates sales. The products are for research use only, not diagnosis; expansion into clinical diagnostics would require regulatory authorization and additional technology rights.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cytek Biosciences competes with Standard BioTools for immune-profiling research customers, offering fluorescence-based cell-analysis instruments against CyTOF's metal-tag approach. Watch Cytek's instrument sales and repeat reagent purchases by research laboratories and biopharmaceutical companies.
10x Genomics competes for the academic and biopharmaceutical research budgets that fund Standard BioTools' tissue-imaging and cell-analysis systems. Its Chromium single-cell tools and Visium and Xenium tissue-analysis platforms make their instrument and consumables sales worth watching.
Quanterix's acquired Akoya tissue-analysis offerings compete with Standard BioTools' Hyperion platform for researchers studying proteins in tissue. For this rivalry, watch Akoya's spatial-biology business rather than Quanterix's Simoa instruments, which measure proteins in blood and other fluids.
Illumina bought Standard BioTools' SomaScan business, leaving Standard BioTools eligible for up to $75 million in additional payments if specified fiscal 2025 and 2026 net-revenue targets are met. Illumina sells DNA-reading instruments and consumables to research and clinical customers; for these payments, watch SomaScan assay services and other SOMAmer-based service and product sales, not its broader sequencing revenue.
Bruker's tools for studying molecules within tissue compete with Standard BioTools' Hyperion platform for tissue-analysis research customers. Its spatial-biology product news is the relevant part of a much broader scientific-instrument business.
Bio-Rad Laboratories competes for life-science research customers with PCR and cell-analysis instruments that rival Standard BioTools' microfluidic qPCR and cytometry systems.
Thermo Fisher Scientific competes for research laboratories' purchases with Applied Biosystems qPCR instruments and flow-cytometry products that rival Standard BioTools' Biomark and CyTOF systems.
Danaher competes for cellular research customers through Beckman Coulter's cell-analysis instruments, which rival Standard BioTools' CyTOF systems.
Agilent Technologies competes for laboratory research spending with cell-analysis and genomics instruments that rival Standard BioTools' cytometry and microfluidic genomics platforms. Watch those instrument lines separately from CrossLab consumables, which can serve laboratories regardless of whose instruments they use.
Bio-Techne offers researchers studying molecular markers in tissue an alternative to Standard BioTools' Hyperion platform. Watch its spatial-biology products rather than treating the whole Diagnostics and Spatial Biology segment, which also sells diagnostic products, as a measure of this rivalry.
Revvity sells cell, gene and protein research technologies to the same drug-discovery and academic laboratories that buy Standard BioTools' cell-analysis and genomics platforms. Its Life Sciences business is the relevant one to watch, rather than its hospital- and medical-laboratory-focused Diagnostics business.
Illumina Inc earningsILMN
Illumina’s report can show how much revenue the SomaScan business it acquired is generating, which bears on whether Standard BioTools receives additional payments.
Focus on SomaScan assay services and other SOMAmer-based product and service sales, not Illumina’s broader sequencing revenue. Strong sales in those activities would make it more plausible that the specified revenue targets—and additional payments to Standard BioTools—are met; weak sales would make those payments less likely.
Bruker Corporation earningsBRKR
Bruker’s spatial-biology products show whether tissue-research customers are adopting the kind of tools that compete with Standard BioTools’ Hyperion platform.
Look for sales or customer adoption specific to Bruker’s spatial-biology products; its much broader company results are not a measure of this rivalry. Stronger demand would point to a more attractive tissue-analysis market, but also a stronger competitor for Hyperion. Weaker demand would mean less market pull, not proof that Standard BioTools is winning customers.
Standard BioTools Inc. earningsThis company
Standard BioTools’ report will show whether laboratories are still buying its mass-cytometry and microfluidics systems and replenishing the consumables those systems use.
Read instrument revenue alongside consumables revenue: instrument sales show whether laboratories are adding systems, while consumables show whether installed systems are being used. Growth in both would indicate that new purchases and ongoing use are supporting revenue; instrument growth without comparable consumables growth would mean new placements are not yet producing matching repeat demand; declines in both would point to weaker purchases or use.
Cytek Biosciences, Inc. earningsCTKB
Cytek’s instrument sales and repeat reagent purchases show demand and ongoing use in immune profiling, where its fluorescence-based tools compete with Standard BioTools’ CyTOF systems.
Read Cytek’s instrument sales together with laboratories’ repeat reagent purchases. Strength in both would show new buying and continued use in immune profiling, while also indicating demand for a competing approach. If Cytek is strong as Standard BioTools’ related instrument or consumables revenue weakens, competitive pressure becomes more concerning. Weak Cytek sales could reflect a soft market, not necessarily a gain for Standard BioTools.
10x Genomics, Inc. earningsTXG
10x Genomics’ instrument and consumables sales show whether academic and biopharmaceutical researchers are still spending on single-cell and tissue-analysis tools, the same budgets Standard BioTools competes for.
Read 10x’s instrument and consumables sales together: the first show whether laboratories are adding platforms, the second whether they keep using them. Strength in both would indicate that research budgets still support tool purchases and use, though 10x competes for those budgets too; weakness in both would point to pressure on customer spending. Only Standard BioTools’ own instrument and consumables results can show whether it is keeping pace or losing share.
